A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

The researchers behind the new AI system explained IPF is a good candidate for this type of technology, since existing ...

Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard ...

This new meta-analysis looked to better solidify connections between atopic dermatitis and environmental irritants, such as ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...